Live feed08:00:00·381dPRReleasevia QuantisnowDESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial CancerByQuantisnow·Wall Street's wire, on your screen.AZN· AstraZeneca PLCHealth Care
